Qiagen (NYSE:QGEN) Earns Hold (C+) Rating from Weiss Ratings

Key Points

• Qiagen received a "hold (C+)" rating from Weiss Ratings following a report, which complements a mix of ratings from other analysts who also have issued hold and buy ratings.
• Qiagen's stock is currently trading at $47.76 and has a consensus price target of $49.40 as reported by MarketBeat.
• Recent quarterly earnings showed Qiagen meeting expectations with $0.60 earnings per share and revenue of $533.54 million, reflecting a 7.7% year-over-year growth.

Qiagen (NYSE:QGEN - Get Free Report)'s stock had its "hold (c+)" rating reissued by research analysts at Weiss Ratings in a report released on Wednesday,Weiss Ratings reports.

Other research analysts have also recently issued reports about the stock. Wall Street Zen cut shares of Qiagen from a "buy" rating to a "hold" rating in a report on Friday, October 3rd. Bank of America raised their target price on shares of Qiagen from $50.00 to $53.00 and gave the stock a "buy" rating in a report on Thursday, June 26th. Cowen restated a "hold" rating on shares of Qiagen in a report on Thursday, August 7th. Barclays set a $53.00 target price on shares of Qiagen and gave the stock an "overweight" rating in a report on Thursday, October 2nd. Finally, UBS Group raised their target price on shares of Qiagen from $48.00 to $50.00 and gave the stock a "neutral" rating in a report on Thursday, August 7th. Three analysts have rated the stock with a Buy rating and nine have given a Hold rating to the company's stock. According to MarketBeat, the company has an average rating of "Hold" and a consensus price target of $49.40.

Qiagen Trading Up 2.1%

Qiagen stock opened at $47.76 on Wednesday. The firm has a 50 day simple moving average of $47.21 and a 200-day simple moving average of $45.40. The company has a debt-to-equity ratio of 0.25, a current ratio of 1.61 and a quick ratio of 1.35. The stock has a market capitalization of $10.62 billion, a PE ratio of 28.22, a price-to-earnings-growth ratio of 2.47 and a beta of 0.66. Qiagen has a 12-month low of $37.63 and a 12-month high of $51.88.

Qiagen (NYSE:QGEN - Get Free Report) last posted its quarterly earnings data on Tuesday, August 5th. The company reported $0.60 earnings per share (EPS) for the quarter, meeting the consensus estimate of $0.60. The business had revenue of $533.54 million during the quarter, compared to analysts' expectations of $523.97 million. Qiagen had a net margin of 18.30% and a return on equity of 14.77%. The business's revenue was up 7.7% on a year-over-year basis. During the same period last year, the firm posted $0.55 earnings per share. Qiagen has set its Q3 2025 guidance at 0.580- EPS. FY 2025 guidance at 2.350-2.350 EPS. As a group, equities research analysts expect that Qiagen will post 2.26 EPS for the current fiscal year.

Institutional Investors Weigh In On Qiagen

Hedge funds have recently made changes to their positions in the company. SVB Wealth LLC purchased a new stake in shares of Qiagen in the 1st quarter valued at approximately $31,000. MAI Capital Management lifted its position in shares of Qiagen by 998.9% in the 2nd quarter. MAI Capital Management now owns 978 shares of the company's stock valued at $47,000 after acquiring an additional 889 shares in the last quarter. Farther Finance Advisors LLC lifted its position in shares of Qiagen by 400.5% in the 2nd quarter. Farther Finance Advisors LLC now owns 1,061 shares of the company's stock valued at $51,000 after acquiring an additional 849 shares in the last quarter. Allworth Financial LP lifted its position in shares of Qiagen by 260.1% in the 2nd quarter. Allworth Financial LP now owns 1,102 shares of the company's stock valued at $53,000 after acquiring an additional 796 shares in the last quarter. Finally, GAMMA Investing LLC increased its stake in Qiagen by 375.5% in the 3rd quarter. GAMMA Investing LLC now owns 1,241 shares of the company's stock valued at $55,000 after buying an additional 980 shares during the period. Hedge funds and other institutional investors own 70.00% of the company's stock.

Qiagen Company Profile

QIAGEN NV is a holding company, which engages in the provision of Sample to Insight solutions that enable customers to gain valuable molecular insights from samples containing the building blocks of life. The company sample technologies isolate and process DNA, RNA, and proteins from blood, tissue, and other materials.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.